Smart-Money SignalNeutral · 48/100— Insiders are net sellers over 90 days (-$1.2M, 11 sales vs 8 buys)
Revenue$31.7M
Net Income-$62.8M
EPS$-0.17
Gross Margin41.1%
Market Cap$2.3B
Price Performance
Historical data including institutional events
Company Profile
D
David Hung
CEO & Executive Director
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
The companyâs lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.
The company was founded in 2018 and is headquartered in New York, New York.
